The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. (Q53153100)

11 May 2018

title

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. (English)

1 reference

11 May 2018

0 references

R A Wilcox

1

1 reference

11 May 2018

K Ristow

2

1 reference

11 May 2018

T M Habermann

3

1 reference

11 May 2018

D J Inwards

4

1 reference

11 May 2018

I N M Micallef

5

1 reference

11 May 2018

P B Johnston

6

1 reference

11 May 2018

J P Colgan

7

1 reference

11 May 2018

G S Nowakowski

8

1 reference

11 May 2018

S M Ansell

9

1 reference

11 May 2018

T E Witzig

10

1 reference

11 May 2018

S N Markovic

11

1 reference

11 May 2018

L Porrata

12

1 reference

11 May 2018

publication date

24 May 2011

1 reference

11 May 2018

published in

Leukemia

1 reference

11 May 2018

volume

25

1 reference

11 May 2018

issue

9

1 reference

11 May 2018

page(s)

1502-1509

1 reference

11 May 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Cancer-associated myeloproliferation: old association, new therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Rituximab: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Myeloid-derived suppressor cells: a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Evaluation of the Coulter Counter model S-Plus IV

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Stimulation of hematopoiesis and bone marrow suppressor cells by the subcutaneous injection of linoleic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Elevated serum BLyS levels in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.112

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.112

1 reference

11 May 2018

1 reference

11 May 2018